Why are tumour blood vessels abnormal and why is it important to know?
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Tumour blood vessels differ from their normal counterparts for reasons that have received little attention. We report here that they are of at least six distinct types, we describe how each forms, and, looking forward, encourage the targeting of tumour vessel subsets that have lost their vascular endothelial growth factor-A (VEGF-A) dependency and so are likely unresponsive to anti-VEGF-A therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although many in vitro microvessel models have been developed, none of them can actually reproduce the architecture of capillaries seen in a tumor [217,218].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [217]
Experimental — accuracy not yet measuredIn the citing paper
“The vasculature of tumors is very different from the blood vessels that supply healthy tissues, especially in terms of heterogeneity, permeability, multidirectional blood flow, and unordered distribution throughout the tumor160.”
From Tumor-on-a-chip: from bioinspired design to biomedical application (2021) · cites this paper as [160]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187 · cited 1×
“Furthermore, recent successes with agents that block VEGF-A or its receptors have supported Folkman’s (1971) thesis that anti-angiogenesis can be a useful supplement to traditional tumour therapy.”
BackgroundTumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391 · cited 1×
“As was noted more than 20 years ago, tumour angiogenesis shares many analogies with wound healing (Dvorak, 1986).”
BackgroundSelf-citationTransplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis
Hellström, M., Phng, L.-K., Hofmann, J. J., Wallgard, E., Coultas, L., Lindblom, P., Alva, J., Nilsson, A.-K., Karlsson, L., Gaiano, N., et al. (2007) · Nature · doi:10.1038/nature05571 · Cited by 1,775 · cited 1×
“…of endothelial cells: non-dividing ‘tip’ cells at the leading edge that extend filopodia and sprouts in response to VEGF-A gradients and ‘stalk’ cells that follow behind, divide and exhibit reduced filopodia and sprouting because of signalling through the Notch/delta 4 axis (Hellstrom et al, 2007).”
BackgroundBergers, G., Song, S., Meyer-Morse, N., Bergsland, E., & Hanahan, D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17929 · Cited by 1,370 · cited 1×
“…that anti-VEGF/VEGFR approaches have effectively treated mouse tumours at early stages of their development, but have proved to be less successful in treating established mouse tumours that contain large numbers of more mature, smooth muscle-cell-coated blood vessels (Bergers et al, 2003).”
BackgroundBergers, G., Song, S., Meyer-Morse, N., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317929 · Cited by 1,192
Lessons from phase III clinical trials on anti-VEGF therapy for cancer
Jain, R. K., Duda, D. G., Clark, J. W., & Loeffler, J. S. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0403 · Cited by 1,039 · cited 2×
“Agents that neutralise VEGF (e.g., Avastin, VEGF-TRAP) or its receptors have provided proof of principle that anti-angiogenesis can be a useful adjunct to tumour therapy (Jain et al, 2006).”
BackgroundRuhrberg, C., Gerhardt, H., Golding, M., Watson, R., Ioannidou, S., Fujisawa, H., Betsholtz, C., & Shima, D. T. (2002) · Genes & Development · doi:10.1101/gad.242002 · Cited by 914 · cited 2×
“Mice engineered to express only VEGF-A120 develop to term but generate a capillary network with larger-sized vessels and fewer branch points (Ruhrberg et al, 2002).”
BackgroundLee, S., Jilani, S. M., Nikolova, G. V., Carpizo, D., & Iruela-Arispe, M. L. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200409115 · Cited by 703 · cited 2×
“Similar large, MV-like vessels can be generated by still smaller VEGF-As that result from matrix metalloprotease cleavage (Lee et al, 2005).”
BackgroundVasculogenic Mimicry and Tumor Angiogenesis
Folberg, R., Hendrix, M. J. C., & Maniotis, A. J. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64739-6 · Cited by 684 · cited 1×
“…and DV result, respectively, from arteriogenesis and venogenesis. aIn addition, red blood-cell-filled spaces lined by tumour cells rather than by vascular endothelium have been described in some tumours, particularly ocular melanomas, and are referred to as ‘vascular mimicry’ (Folberg et al, 2000).”
Background
Cited by
Items 101–200 of 612
Granhøj, J. S., Jensen, A. W. P., Presti, M., Met, Ö., Svane, I. M., & Donia, M. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2064711 · Cited by 82
Bu, M. T., Chandrasekhar, P., Ding, L., & Hugo, W. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108211 · Cited by 84
“VEGFA stimulates the proliferation of endothelial cells, forming a structurally abnormal and leaky tumor vasculature (Baluk, Hashizume, & McDonald, 2005; Ferrara, 2021; Jain, 2003, 2005; Nagy, Chang, Dvorak, & Dvorak, 2009).”
BackgroundPotential use of Folate-appended Methyl-β-Cyclodextrin as an Anticancer Agent
Onodera, R., Motoyama, K., Okamatsu, A., Higashi, T., & Arima, H. (2013) · Scientific Reports · doi:10.1038/srep01104 · Cited by 78
Support of Tumor Endothelial Cells by Chemokine Receptors
Salazar, N., & Zabel, B. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00147 · Cited by 72
Silica-based nanoparticles for therapeutic protein delivery
Yu, M., Gu, Z., Ottewell, T., & Yu, C. (2017) · Journal of Materials Chemistry B · doi:10.1039/c7tb00244k · Cited by 74
Biomineralized Biohybrid Algae for Tumor Hypoxia Modulation and Cascade Radio-Photodynamic Therapy
Li, W., Zhong, D., Hua, S., Du, Z., & Zhou, M. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c14400 · Cited by 72
Sun, L., Wang, J., Liu, J., Li, L., & Xu, Z. P. (2020) · Small Structures · doi:10.1002/sstr.202000112 · Cited by 77
How VEGF-A and its splice variants affect breast cancer development – clinical implications
Kawas, H. A., Saaid, I., Jank, P., Westhoff, C. C., Denkert, C., Pross, T., Weiler, K. B. S., & Karsten, M. M. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00665-w · Cited by 81
Paku, S., Dezső, K., Bugyik, E., Tóvári, J., Tímár, J., Nagy, P., László, V., Klepetko, W., & Döme, B. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.05.033 · Cited by 90
Targeting pH regulating proteins for cancer therapy–Progress and limitations
Parks, S. K., & Pouysségur, J. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.01.007 · Cited by 77
“the root of tumour acidosis is the hallmark cancer feature of an abnormal/chaotic vasculature, which results in poor blood delivery and fluid clearance [5].”
BackgroundAngiogenic role of miR-20a in breast cancer
Luengo‐Gil, G., González‐Billalabeitia, E., Perez-Henarejos, S. A., Manzano, E. N., Cháves-Benito, A., García-Martínez, E., García-Garré, E., Vicente, V., & de la Peña, F. A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0194638 · Cited by 71
Multifunctional Polymeric Micelles for Cancer Therapy
Jin, G., Rejinold, N. S., & Choy, J. (2022) · Polymers · doi:10.3390/polym14224839 · Cited by 77
“The resulting structural abnormality makes the tumor blood vessels highly permeable [39].”
BackgroundAngiostatic treatment prior to chemo- or photodynamic therapy improves anti-tumor efficacy
Weiss, A., Bonvin, D., Berndsen, R. H., Scherrer, E., Wong, T. J., Dyson, P. J., Griffioen, A. W., & Nowak-Sliwinska, P. M. (2015) · Scientific Reports · doi:10.1038/srep08990 · Cited by 77
Yang, X., Zhang, Y., Yang, Y., Lim, S., Cao, Z., Rak, J. W., & Cao, Y. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1309629110 · Cited by 74
The Use of Agonistic Anti-CD40 Therapy in Treatments for Cancer
Khong, A., Nelson, D. J., Nowak, A. K., Lake, R. A., & Robinson, B. W. S. (2012) · International Reviews of Immunology · doi:10.3109/08830185.2012.698338 · Cited by 69
“On the other hand, if the targets are tumor-resident immune cells and tumors do not perfuse well on account of chaotic vasculature [30], then the intratumoral approach may be a better option.”
Vascular Growth in Health and Disease
Persson, A. B., & Buschmann, I. R. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00014 · Cited by 69
“Mother/feeding vessel formation requires BM degradation, pericyte detachment, and vascular enlargement (Nagy et al., 2009).”
InfluentialAngiogenesis and Metabolism: Entwined for Therapy Resistance
Jiménez-Valerio, G., & Casanovas, O. (2017) · Trends in cancer · doi:10.1016/j.trecan.2016.11.007 · Cited by 68
“Some of these areas have impaired vascular 65 function and lead to regions of lowered perfusion and hypoxia[8].”
BackgroundZhu, J., Zhang, C., Christensen-Jeffries, K. M., Zhang, G., Harput, S., Dunsby, C. W., Huang, P., & Tang, M. (2022) · Ultraschall in der Medizin - European Journal of Ultrasound · doi:10.1055/a-1917-0016 · Cited by 68
“Furthermore, it was reported that the overall blood flow velocity tends to be lower in tumors than in normal tissues [30].”
Busch, T. M., Xing, X., Yu, G., Yodh, A. G., Wileyto, E. P., Wang, H. W., Durduran, T., Zhu, T. C., & Wang, K. K. H. (2009) · Photochemical & Photobiological Sciences · doi:10.1039/b9pp00004f · Cited by 70
Hypoxia-inducible factor in cancer: from pathway regulation to therapeutic opportunity
Ortmann, B. M. (2024) · BMJ Oncology · doi:10.1136/bmjonc-2023-000154 · Cited by 67
Si, P., Yuan, E. C., Liba, O., Winetraub, Y., Yousefi, S., SoRelle, E. D., Yecies, D. W., Dutta, R., & de la Zerda, A. (2018) · ACS Nano · doi:10.1021/acsnano.8b03862 · Cited by 68
Enhancing the efficacy of immunotherapy using radiotherapy
Keam, S., Gill, S., Ebert, M. A., Nowak, A. K., & Cook, A. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1169 · Cited by 69
“distinguished from normal vasculature through numerous cell-surface molecules and extracellular matrix proteins, which are mostly associated with stimulating tumor angiogenesis; this may confer treatment resistance.(91,92) Low-dose fractionated radiotherapy (2 Gy, five fractions per week) has been reported to normalis…”
BackgroundTomaszewski, M. R., Gehrung, M., Joseph, J. A., Quirós-González, I., Disselhorst, J. A., & Bohndiek, S. E. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1033 · Cited by 66
“Diffusion-limited hypoxia emerges early in tumour development, as rapidly proliferating cancer cells experience a gradient of hypoxia with increasing distance from the nearest perfused blood vessel (3).”
BackgroundHypoxia induces immunosuppression, metastasis and drug resistance in pancreatic cancers
Zhang, H., Cao, K., Xiang, J., Zhang, M., Zhu, M., & Xi, Q. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216345 · Cited by 72
Advancing cancer research using bioprinting for tumor-on-a-chip platforms
Knowlton, S., Joshi, A., Yenilmez, B., Ozbolat, I. T., Chua, C. K., Khademhosseini, A., & Tasoglu, S. (2016) · International Journal of Bioprinting · doi:10.18063/ijb.2016.02.003 · Cited by 65
“Tumor vasculature differs greatly from the vessels that supply healthy tissue, specifically in the heterogeneity, permeability, multi-directional blood flow, and irregular distribution throughout the tumor([21]).”
BackgroundAlsaif, N. A., Taghour, M. S., Alanazi, M. M., Obaidullah, A. J., Almehizia, A. A., Alanazi, M. M., Aldawas, S., Elwan, A., & Elkady, H. (2021) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2021.1915303 · Cited by 67
“Furthermore, it has a significant role in tumour progression and development 9,10 .”
3D Multiparametric Photoacoustic Computed Tomography of Primary and Metastatic Tumors in Living Mice
Kim, J., Lee, J., Choi, S., Lee, H., Yang, J., Jeon, H., Sung, M., Kim, W. J., & Kim, C. (2024) · ACS Nano · doi:10.1021/acsnano.3c12551 · Cited by 74
Pterygium—The Good, the Bad, and the Ugly
Acker, S. I. V., den Bogerd, B. V., Haagdorens, M. K. C., Siozopoulou, V., Dhubhghaill, S. N., Pintelon, I., & Koppen, C. (2021) · Cells · doi:10.3390/cells10071567 · Cited by 76
“Tumor angiogenesis occurs in an uneven, chaotic and serpentine manner that is characterized by irregular branches and arterio-venous shunts [45].”
BackgroundFluid mechanics in circulating tumour cells: Role in metastasis and treatment strategies
Rajput, S., Sharma, P. K., & Malviya, R. (2023) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2023.100158 · Cited by 75
Advances in Degradable Embolic Microspheres: A State of the Art Review
Doucet, J., Kiri, L., O’Connell, K., Kehoe, S., Lewandowski, R. J., Liu, D. M., Abraham, R. J., & Boyd, D. (2018) · Journal of Functional Biomaterials · doi:10.3390/jfb9010014 · Cited by 69
“Firstly, vascular tumors (including uterine fibroids) tend to show significant increases in blood flow relative to their non-diseased counterparts, and preferentially draw microspheres from the circulation to the tumor [54].”
BackgroundLee, S., Kim, S., Koo, D.-J., Yu, J., Cho, H., Lee, H., Song, J. M., Kim, S., Min, D., & Jeon, N. L. (2020) · ACS Nano · doi:10.1021/acsnano.0c05110 · Cited by 68
Silini, A. R., Ghilardi, C., Figini, S., Sangalli, F., Fruscio, R., Dahse, R., Pedley, R. B., Giavazzi, R., & Bani, M. R. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0862-8 · Cited by 66
“They are heterogeneous in organization, structure, and function, and branch irregularly originating a vasculature unevenly distributed and chaotic [4].”
BackgroundLee, J., Borboa, A. K., Chun, H. B., Baird, A., & Eliceiri, B. P. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2740 · Cited by 68
Pore-engineered nanoarchitectonics for cancer therapy
Sutrisno, L., & Ariga, K. (2023) · NPG Asia Materials · doi:10.1038/s41427-023-00469-w · Cited by 64
Hoffmann, D., Dvořáková, T., Stroobant, V., Bouzin, C., Daumerie, A., Solvay, M., Klaessens, S., Letellier, M.-C., Renauld, J., van Baren, N., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0040 · Cited by 64
“TDO-positive tumor vessels often displayed abnormal features that were similar to the vascular anomalies previously observed in tumors (42).”
BackgroundResultDuncan, R., Sat-Klopsch, Y.-N., Burger, A. M., Bibby, M. C., Fiebig, H., & Sausville, E. A. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2209-7 · Cited by 68
“different classes of angiogenic vessels [25], vessel disorganisation and heterogeneity of tumour perfusion) and intratumoural biological barriers (e.”
BackgroundEckert, F., Zwirner, K., Boeke, S., Thorwarth, D., Zips, D., & Huber, S. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00407 · Cited by 62
“In addition, tumor vessels often show aberrant architecture, may have dilated or blind-ending lumina, and lack normal vessel walls (1).”
BackgroundSchumacher, O., Galvao, D. A., Taaffe, D. R., Chee, R., Spry, N. A., & Newton, R. U. (2020) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-020-0245-z · Cited by 70
Dey, M., Kim, M., Dogan, M., Nagamine, M., Kozhaya, L., Celik, N., Unutmaz, D., & Ozbolat, I. T. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202203966 · Cited by 83
Anti‐VEGF DNA‐based aptamers in cancer therapeutics and diagnostics
Riccardi, C., Napolitano, E., Platella, C., Musumeci, D., Melone, M. A. B., & Montesarchio, D. (2020) · Medicinal Research Reviews · doi:10.1002/med.21737 · Cited by 68
“stimulates the proliferation and survival of ECs, leading to the formation of new blood vessels, which may be structurally abnormal and leaky.(86,102,103) Numerous studies have shown that VEGF is overexpressed in the vast majority of human solid tumors, including lung, breast, gastrointestinal tract,(110) liver,(101)…”
BackgroundChallenges and Opportunities Associated With Drug Delivery for the Treatment of Solid Tumors
Paresishvili, T., & Kakabadze, Z. (2023) · Oncology Reviews · doi:10.3389/or.2023.10577 · Cited by 68
“There are reports that the tumor blood vessels are more numerous at the tumor-host interface than in the central regions [18].”
BackgroundKawczyk‐Krupka, A., Wawrzyniec, K., Musiol, S., Potempa, M., Bugaj, A. M., & Sieroń, A. (2015) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2015.10.001 · Cited by 59
The tumor microenvironment in renal cell cancer
Mier, J. W. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000512 · Cited by 66
Vessel calibre—a potential MRI biomarker of tumour response in clinical trials
Emblem, K. E., Farrar, C. T., Gerstner, E. R., Batchelor, T. T., Borra, R. J. H., Rosen, B. R., Sorensen, A. G., & Jain, R. K. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.126 · Cited by 59
Garcia, E., Becker, V. G. C., McCullough, D. J., Stabley, J. N., Gittemeier, E. M., Opoku-Acheampong, A. B., Sieman, D. W., & Behnke, B. J. (2016) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00266.2016 · Cited by 57
Li, C., Maishi, N., Annan, D. A., Young, M. F., Morimoto, H., Morimoto, M., Nam, J.-M., Hida, Y., & Hida, K. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01423-w · Cited by 65
“Tumor vasculature is structurally abnormal relative to normal vasculature and is characterized by highly permeable and leaky blood vessels [1].”
BackgroundBerenguer‐Daizé, C., Boudouresque, F., Bastide, C., Tounsi, A., Benyahia, Z., Acunzo, J., Dussault, N., Delfino, C., Baeza, N., Daniel, L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0691 · Cited by 58
Novel peptide probes to assess the tensional state of fibronectin fibers in cancer
Arnoldini, S., Moscaroli, A., Chabria, M., Hilbert, M., Hertig, S., Schibli, R., Béhé, M. P., & Viola Vogel, B. (2017) · Nature Communications · doi:10.1038/s41467-017-01846-0 · Cited by 59
Davis, G. E., Norden, P. R., & Bowers, S. (2015) · Connective Tissue Research · doi:10.3109/03008207.2015.1066781 · Cited by 58
“It is known that EC-pericyte interactions are impaired within the tumor microenvironment and this will account for the abnormal vasculature that is observed (14,23,24,87).”
BackgroundZhen, M., Shu, C., Li, J., Zhang, G., Wang, T., Luo, Y., Zou, T., Deng, R., Fang, F., Lei, H. C., et al. (2015) · Science China Materials · doi:10.1007/s40843-015-0089-3 · Cited by 54
Platelets as messengers of early-stage cancer
Sabrkhany, S., Kuijpers, M. J. E., Egbrink, M. G. A. O., & Griffioen, A. W. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09956-4 · Cited by 59
Tortuous Microvessels Contribute to Wound Healing via Sprouting Angiogenesis
Chong, D. C., Yu, Z., Brighton, H. E., Bear, J. E., & Bautch, V. L. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309993 · Cited by 58
Lipoic acid and lipoic acid analogs in cancer metabolism and chemotherapy
Bingham, P. M., Stuart, S. D., & Zachar, Z. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.966816 · Cited by 55
“tumor cells require that this vital mitochondrial metabolism be regulated differently than in most normal cells, perhaps coopting (in an altered, unregulated fashion) the corresponding machinery designed for normal wound healing [49,50].”
BackgroundTaleb, M., Ding, Y., Wang, B., Yang, N., Han, X., Du, C., Qi, Y., Zhang, Y., Sabet, Z. F., Alanagh, H. R., et al. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201900283 · Cited by 54
Zahra, F. T., Sajib, M. S., Ichiyama, Y., Akwii, R. G., Tullar, P., Cobos, C. J., Minchew, S. A., Doçi, C. L., Zheng, Y., Kubota, Y., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-48053-z · Cited by 51
Schoenmann, N., Tannenbaum, N., Hodgeman, R. M., & Raju, R. P. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166769 · Cited by 57
Levy, T., Voeltzke, K., Hruby, L. A., Alasad, K., Bas, Z., Snaebjornsson, M. T., Marciano, R., Scharov, K., Planque, M., Vriens, K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48386-y · Cited by 56
Quest for Efficacious Next-Generation Taxoid Anticancer Agents and Their Tumor-Targeted Delivery
Ojima, I., Wang, X., Jing, Y., & Wang, C. (2018) · Journal of Natural Products · doi:10.1021/acs.jnatprod.7b01012 · Cited by 53
Insights on CTC Biology and Clinical Impact Emerging from Advances in Capture Technology
Bailey, P. C., & Martin, S. S. (2019) · Cells · doi:10.3390/cells8060553 · Cited by 55
“Tumor vasculature is improperly formed, tortuous, leaky, and possessive of blind shunts [132].”
BackgroundNanomedicine for prostate cancer using nanoemulsion: A review
Sasikumar, A., & Kamalasanan, K. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.06.001 · Cited by 56
Improving homing in T cell therapy
Vignali, D., & Kallikourdis, M. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.06.009 · Cited by 54
3D Bioprinting: Recent Trends and Challenges
Chameettachal, S., Yeleswarapu, S., Sasikumar, S., Shukla, P., Hibare, P., Bera, A. K., Bojedla, S. S. R., & Pati, F. (2019) · Journal of the Indian Institute of Science · doi:10.1007/s41745-019-00113-z · Cited by 57
The Interplay of Dysregulated pH and Electrolyte Imbalance in Cancer
Alfarouk, K. O., Ahmed, S. B. M., Ahmed, A., Elliott, R. L., Ibrahim, M. E., Ali, H. S., Wales, C. C., Nourwali, I., Aljarbou, A. N., Bashir, A. H. H., et al. (2020) · Cancers · doi:10.3390/cancers12040898 · Cited by 57
Physical Exercise and the Hallmarks of Breast Cancer: A Narrative Review
García‐Chico, C., López‐Ortiz, S., Peñín‐Grandes, S., Pinto-Fraga, J., Valenzuela, P. L., Emanuele, E., Ceci, C., Graziani, G., Fiuza‐Luces, C., Lista, S., et al. (2023) · Cancers · doi:10.3390/cancers15010324 · Cited by 68
Marien, K. M., Croons, V., Waumans, Y., Sluydts, E., Schepper, S. D., Andries, L. J., Waelput, W., Fransén, E., Vermeulen, P. B., Kockx, M. M., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161496 · Cited by 55
Davies, A. E., & Albeck, J. G. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00044 · Cited by 53
“However, local derangements in vascular structure often impair infiltration of these tumor-killing cells (Nagy et al., 2009).”
BackgroundAutophagy as a mechanism for anti-angiogenic therapy resistance
Chandra, A., Rick, J. W., Yagnik, G., & Aghi, M. K. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.031 · Cited by 56
“It is also expected that tumors will not express the full spectrum of VEGF subgroups, which are likely responsible for helping vessels mature normally [11].”
BackgroundHepatocellular Carcinoma: Old and Emerging Therapeutic Targets
Pessino, G., Scotti, C., Maggi, M., & Immuno-Hub Consortium (2024) · Cancers · doi:10.3390/cancers16050901 · Cited by 53
“…include activation by des-gamma carboxy prothrombin (DCP), which is highly secreted by HCC cells [182]; interaction with other receptors, such as EGFR, integrin, beta-catenin, CD44, MUC1, and FAK [177,183,184]; hypoxia and miRNA loss [185]; and receptor-activating mutations and amplification [177].”
Xue, W., Du, X., Wu, H., Liu, H., Xie, T., Tong, H., Chen, X., Guo, Y., & Zhang, W. (2017) · Scientific Reports · doi:10.1038/s41598-017-14341-9 · Cited by 48
Qu, Y., Dunn, Z. S., Chen, X., MacMullan, M. A., Cinay, G. E., Wang, H.-Y., Liu, J., Hu, F., & Wang, P. (2022) · Human Gene Therapy · doi:10.1089/hum.2021.050 · Cited by 50
“40 This leakiness causes tumor-associated collagen to be exposed to molecules in the blood preferentially to other tissues.”
Nanotechnological Strategies for Therapeutic Targeting of Tumor Vasculature
Ding, Y., Li, S., & Nie, G. (2013) · Nanomedicine · doi:10.2217/nnm.13.106 · Cited by 51
Magnetotaxis Enables Magnetotactic Bacteria to Navigate in Flow
Yazdi, S. R., Nosrati, R., Stevens, C. A., Vogel, D., Davies, P. L., & Escobedo, C. (2017) · Small · doi:10.1002/smll.201702982 · Cited by 46
Pericytes: Problems and Promises for CNS Repair
Laredo, F., Plebanski, J., & Tedeschi, A. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00546 · Cited by 44
Ultrasensitive detection of 3D cerebral microvascular network dynamics in vivo
Pan, Y., You, J., Volkow, N. D., Park, K., & Du, C. (2014) · NeuroImage · doi:10.1016/j.neuroimage.2014.08.051 · Cited by 44
Yang, C. J., Bromma, K., & Chithrani, D. B. (2018) · Cancers · doi:10.3390/cancers10030084 · Cited by 44
“Tumor blood vessels are generally more abundant at the periphery than in central regions [52].”
Hu, Y., Dingerdissen, H., Gupta, S., Kahsay, R., Shanker, V. K., Wan, Q., Yan, C., & Mazumder, R. (2018) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2018.10.021 · Cited by 48
Favia, A., Pafumi, I., Desideri, M., Padula, F., Montesano, C., Passeri, D., Nicoletti, C., Orlandi, A., Bufalo, D. D., Sergi, M., et al. (2016) · Scientific Reports · doi:10.1038/srep18925 · Cited by 45
Lokerse, W. J. M., Bolkestein, M., ten Hagen, T. L. M., de Jong, M., Eggermont, A. M. M., Grüll, H., & Koning, G. A. (2016) · Theranostics · doi:10.7150/thno.14960 · Cited by 43
“In contrast to healthy tissues, tumors exhibit a poorly organized vascular system [1, 2] with endothelial gaps [3, 4] that allow extravasation and accumulation of nanoparticles up to several hundred nanometers [1, 5].”
BackgroundA Window of Opportunity: Targeting Cancer Endothelium to Enhance Immunotherapy
Duru, G., van Egmond, M., & Heemskerk, N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.584723 · Cited by 48
Multiscale topology characterizes dynamic tumor vascular networks
Stolz, B. J., Kaeppler, J., Markelc, B., Braun, F., Lipsmeier, F., Muschel, R. J., Byrne, H. M., & Harrington, H. A. (2022) · Science Advances · doi:10.1126/sciadv.abm2456 · Cited by 60
Cancer-on-a-chip for precision cancer medicine
Liu, L., Wang, H., Chen, R., Song, Y., Wei, W., Baek, D. S. H., Gillin, M., Kurabayashi, K., & Chen, W. (2025) · Lab on a Chip · doi:10.1039/d4lc01043d · Cited by 52
Hoang, M. V., Nagy, J. A., & Senger, D. R. (2010) · Microvascular Research · doi:10.1016/j.mvr.2010.09.001 · Cited by 48
“…hierarchical vascular network formed during normal angiogenesis, pathological angiogenesis is characterized by abnormal angio-architecture and vessel leakiness, resulting in poor vascular perfusion (Fukumura and Jain, 2007; Jain, 2003; Nagy et al., 2009; Nagy and Senger, 2006; Pierce et al., 1995).”
BackgroundSelf-citationKlutzny, S., Lesche, R., Keck, M., Kaulfuß, S., Schlicker, A., Christian, S., Sperl, C., Neuhaus, R., Mowat, J., Steckel, M., et al. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.130 · Cited by 47
Öncül, S., & Cho, M. S. (2023) · Cancers · doi:10.3390/cancers15041282 · Cited by 42
“Blood flow in tumor-associated vessels is inconsistent and may lead to maladjusted circulation [82,84].”
BackgroundPhysical break-down of the classical view on cancer cell invasion and metastasis
Mierke, C. T. (2013) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2012.12.002 · Cited by 53
Bone: A Fertile Soil for Cancer Metastasis
Coughlin, T. R., Romero-Moreno, R., Mason, D. E., Nystrom, L. M., Boerckel, J. D., Niebur, G. L., & Littlepage, L. E. (2017) · Current Drug Targets · doi:10.2174/1389450117666161226121650 · Cited by 42
“Unlike healthy vessels, tumorassociated vasculature frequently exhibits abnormal morphology that results in mixing of arterial and venous flow, even in the same vessels, and new tumor vessel formation may not correlate with local hypoxia [41].”
BackgroundEmerging Links between Control of Mitochondrial Protein ATAD3A and Cancer
Lang, L., Loveless, R., & Teng, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217917 · Cited by 41
“In particular, limited overall blood flow is typical in solid tumors due to highly abnormal tumor vasculature [43].”
BackgroundCurrent Treatments and New Possible Complementary Therapies for Epithelial Ovarian Cancer
Garrido, M. P., Fredes, A. N., Lobos‐González, L., Valenzuela, M., Vera, D. B., & Romero, C. (2021) · Biomedicines · doi:10.3390/biomedicines10010077 · Cited by 52
“The inhibition of VEGF-mediated signalling leads to tumour vasculature normalization, improving chemotherapy delivery which results in increased tumour toxicity and a decreased formation of ascites fluid [91,92].”
BackgroundTroendle, E. P., Khan, A., Searson, P. C., & Ulmschneider, M. B. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.11.010 · Cited by 42
“Often there is no preferred blood flow direction or the vasculature is connected only to feeder arteries with no draining veins [29].”
Cavaco, A. C. M., Rezaei, M., Niland, S., & Eble, J. A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112355 · Cited by 43
“Tumor vasculature is unexpectedly complex and can be classified into at least six types [136].”
BackgroundHoming Peptides for Cancer Therapy
Lingasamy, P., & Teesalu, T. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-58174-9_2 · Cited by 43
Mechanisms of skin vascular maturation and maintenance captured by longitudinal imaging of live mice
Kam, C. Y., Singh, I., Gonzalez, D. G., Matte-Martone, C. C., Solá, P., Solanas, G., Bonjoch, J., Marsh, E. D., Hirschi, K. K., & Greco, V. (2023) · Cell · doi:10.1016/j.cell.2023.04.017 · Cited by 39
Emerging nanotechnological approaches to regulating tumor vasculature for cancer therapy
Wang, C., Xu, J., Zhang, Y., & Nie, G. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.017 · Cited by 41
Xiao, M., Xie, J., Wu, Y., Wang, G., Qi, X., Liu, Z., Wang, Y., Wang, X., Hoque, A., Oakhill, J. S., et al. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-0528-y · Cited by 41
Li, Z., Ning, F., Wang, C., Yu, H., Ma, Q., & Sun, Y. (2021) · Nanoscale · doi:10.1039/d1nr03387e · Cited by 46
Mechanical regulation of the early stages of angiogenesis
Barrasa-Ramos, S., Dessalles, C. A., Hautefeuille, M., & Barakat, A. I. (2022) · Journal of The Royal Society Interface · doi:10.1098/rsif.2022.0360 · Cited by 50
Induction of mitophagy-mediated antitumor activity with folate-appended methyl-β-cyclodextrin
Kameyama, K., Motoyama, K., Tanaka, N., Yamashita, Y., Higashi, T., & Arima, H. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s133482 · Cited by 43
“In general, blood vessels around tumors are leaky(42,43) and poorly organized.(44,45) This can cause the enhancement of the interstitial fluid pressure of tumor tissues and inhibition of the blood supply to them, resulting in the poor drug accumulation.”
Ternifi, R., Wang, Y., Gu, J., Polley, E. C., Carter, J. M., Pruthi, S., Boughey, J. C., Fazzio, R. T., Fatemi, M., & Alizad, A. (2022) · European Radiology · doi:10.1007/s00330-022-08815-2 · Cited by 40
“In turn, the demand for additional oxygen in growing tumors leads to formation of leaky, fragile, tortuous vessels [4].”
BackgroundResultInfluentialThe buckling of capillaries in solid tumours
MacLaurin, J., Chapman, J., Jones, G. W., & Roose, T. (2012) · Proceedings of the Royal Society A Mathematical Physical and Engineering Sciences · doi:10.1098/rspa.2012.0418 · Cited by 39
Chitoran, E., Rotaru, V., Stefan, D. C., Gullo, G., & Simion, L. (2025) · Cancers · doi:10.3390/cancers17071126 · Cited by 46
Metadata
- Authors
- Nagy, J. A., Chang, S.-H., Dvorak, A. M., & Dvorak, H. F.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Corresponding author
- Dvorak, H F
- ORCID
- Nagy, J A
- Venue
- British Journal of Cancer
- Published
- 2009-02-24
- Volume
- 100
- Issue
- 6
- Pages
- 865-869
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC2661770
- OpenAlex
- W2063556542
- Cited by
- 611
- References
- 38
- Citations by year
- 2026: 30 · 2025: 39 · 2024: 62 · 2023: 47 · 2022: 50 · 2021: 53 · 2020: 61 · 2019: 47 · 2018: 51 · 2017: 48 · 2016: 22 · 2015: 16 · 2014: 12 · 2013: 18 · 2012: 20
- FWCI
- 1.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- British Journal of Cancer (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Foundation for Cancer Research
- National Heart, Lung, and Blood Institute (R01HL064402, HL-64402)
- National Cancer Institute (P01 CA 92644, P01CA092644)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- tumor vasculature, VEGF-A, anti-VEGF therapy, tumor angiogenesis, anti-angiogenic therapy resistance
- MeSH terms
- Animals, Blood Vessels, Capillaries, Humans, Neoplasms, Neovascularization, Pathologic, Vascular Endothelial Growth Factor A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.